Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma.

Lorch G, Sivaprakasam K, Zismann V, Perdigones N, Contente-Cuomo T, Nazareno A, Facista S, Wong S, Drenner K, Liang WS, Amann JM, Sinicropi-Yao SL, Koenig MJ, La Perle K, Whitsett TG, Murtaza M, Trent JM, Carbone DP, Hendricks WPD.

Clin Cancer Res. 2019 Oct 1;25(19):5866-5877. doi: 10.1158/1078-0432.CCR-19-1145. Epub 2019 Aug 20.

PMID:
31431454
2.

The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.

Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP.

J Thorac Oncol. 2019 Jun;14(6):1061-1076. doi: 10.1016/j.jtho.2019.02.019. Epub 2019 Feb 27.

PMID:
30825612
3.

Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC.

Sinicropi-Yao SL, Amann JM, Lopez DLY, Cerciello F, Coombes KR, Carbone DP.

J Thorac Oncol. 2019 Feb;14(2):223-236. doi: 10.1016/j.jtho.2018.10.162. Epub 2018 Nov 5.

PMID:
30408569
4.

RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.

Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggini M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V.

Oncogene. 2018 Dec;37(50):6463-6476. doi: 10.1038/s41388-018-0424-8. Epub 2018 Aug 3.

5.

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations.

Yamada T, Amann JM, Tanimoto A, Taniguchi H, Shukuya T, Timmers C, Yano S, Shilo K, Carbone DP.

Mol Cancer Ther. 2018 Jan;17(1):17-25. doi: 10.1158/1535-7163.MCT-17-0146. Epub 2017 Oct 27.

6.

Wideband acoustic immittance in children with Down syndrome: prediction of middle-ear dysfunction, conductive hearing loss and patent PE tubes.

Hunter LL, Keefe DH, Feeney MP, Brown DK, Meinzen-Derr J, Elsayed AM, Amann JM, Manickam V, Fitzpatrick D, Shott SR.

Int J Audiol. 2017 Sep;56(9):622-634. doi: 10.1080/14992027.2017.1314557. Epub 2017 Apr 22.

7.

A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.

Kaufman JM, Yamada T, Park K, Timmers CD, Amann JM, Carbone DP.

Cancer Res. 2017 Jan 1;77(1):153-163. doi: 10.1158/0008-5472.CAN-16-1639. Epub 2016 Nov 7.

8.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.

Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG, Morita S, Carbone DP.

J Thorac Oncol. 2016 Nov;11(11):1927-1939. doi: 10.1016/j.jtho.2016.07.017. Epub 2016 Aug 3.

9.

Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.

Yamada T, Amann JM, Fukuda K, Takeuchi S, Fujita N, Uehara H, Iwakiri S, Itoi K, Shilo K, Yano S, Carbone DP.

Cancer Res. 2015 Oct 1;75(19):4188-97. doi: 10.1158/0008-5472.CAN-15-0858. Epub 2015 Aug 20.

10.

EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.

Arasada RR, Amann JM, Rahman MA, Huppert SS, Carbone DP.

Cancer Res. 2014 Oct 1;74(19):5572-84. doi: 10.1158/0008-5472.CAN-13-3724. Epub 2014 Aug 14.

11.

LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.

Kaufman JM, Amann JM, Park K, Arasada RR, Li H, Shyr Y, Carbone DP.

J Thorac Oncol. 2014 Jun;9(6):794-804. doi: 10.1097/JTO.0000000000000173.

12.

In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers.

Kikuchi T, Hassanein M, Amann JM, Liu Q, Slebos RJ, Rahman SM, Kaufman JM, Zhang X, Hoeksema MD, Harris BK, Li M, Shyr Y, Gonzalez AL, Zimmerman LJ, Liebler DC, Massion PP, Carbone DP.

Mol Cell Proteomics. 2012 Oct;11(10):916-32. Epub 2012 Jul 3.

13.

Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.

Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP.

J Thorac Oncol. 2010 Feb;5(2):169-78. doi: 10.1097/JTO.0b013e3181c8cbd9.

14.

Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control.

Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW.

Mol Cell. 2008 Apr 11;30(1):61-72. doi: 10.1016/j.molcel.2008.02.030.

15.

Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.

Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW.

EMBO J. 2008 Apr 9;27(7):1017-28. doi: 10.1038/emboj.2008.51. Epub 2008 Mar 20.

16.

Novel strategies for the treatment of lung cancer: modulation of eicosanoids.

Backlund MG, Amann JM, Johnson DH.

J Clin Oncol. 2008 Feb 20;26(6):825-7. doi: 10.1200/JCO.2007.14.9583. No abstract available.

PMID:
18281650
17.

Myeloid translocation gene family members associate with T-cell factors (TCFs) and influence TCF-dependent transcription.

Moore AC, Amann JM, Williams CS, Tahinci E, Farmer TE, Martinez JA, Yang G, Luce KS, Lee E, Hiebert SW.

Mol Cell Biol. 2008 Feb;28(3):977-87. Epub 2007 Nov 26.

18.

Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.

Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A, Park KH, Billheimer D, Arteaga CL, Tai HH, DuBois R, Carbone DP, Johnson DH.

Cancer Res. 2007 Jun 15;67(12):5587-93.

19.

Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Amann JM, Chaurand P, Gonzalez A, Mobley JA, Massion PP, Carbone DP, Caprioli RM.

Clin Cancer Res. 2006 Sep 1;12(17):5142-50.

20.

Deletion of Mtgr1 sensitizes the colonic epithelium to dextran sodium sulfate-induced colitis.

Martinez JA, Williams CS, Amann JM, Ellis TC, Moreno-Miralles I, Washington MK, Gregoli P, Hiebert SW.

Gastroenterology. 2006 Aug;131(2):579-88.

PMID:
16890610
21.

Mtgr1 is a transcriptional corepressor that is required for maintenance of the secretory cell lineage in the small intestine.

Amann JM, Chyla BJ, Ellis TC, Martinez A, Moore AC, Franklin JL, McGhee L, Meyers S, Ohm JE, Luce KS, Ouelette AJ, Washington MK, Thompson MA, King D, Gautam S, Coffey RJ, Whitehead RH, Hiebert SW.

Mol Cell Biol. 2005 Nov;25(21):9576-85.

22.

ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.

Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW.

Mol Cell Biol. 2001 Oct;21(19):6470-83.

23.

TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1.

Fenrick R, Wang L, Nip J, Amann JM, Rooney RJ, Walker-Daniels J, Crawford HC, Hulboy DL, Kinch MS, Matrisian LM, Hiebert SW.

Mol Cell Biol. 2000 Aug;20(16):5828-39.

24.

Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.

Fenrick R, Amann JM, Lutterbach B, Wang L, Westendorf JJ, Downing JR, Hiebert SW.

Mol Cell Biol. 1999 Oct;19(10):6566-74.

25.
26.

Incorporation of a stable isotopically labeled amino acid into multiple human apolipoproteins.

Patterson BW, Hachey DL, Cook GL, Amann JM, Klein PD.

J Lipid Res. 1991 Jul;32(7):1063-72.

27.

Intracellular Na+ regulation of Na+ pump sites in cultured vascular smooth muscle cells.

Allen JC, Navran SS, Seidel CL, Dennison DK, Amann JM, Jemelka SK.

Am J Physiol. 1989 Apr;256(4 Pt 1):C786-92.

PMID:
2539727

Supplemental Content

Loading ...
Support Center